My main research interests are in genital and urinary cancers, and I lead a spectrum of clinical studies from phase I to randomised phase III. The majority of the studies are translational phase II studies investigating novel targeted and immune therapies.
MPDL3280A (Anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature (2014) 515(7528):558-62. PMID: 25428503
Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol (2011) 29(16):2178-84. PMID: 21444870
Sequential FDG-PET/CT as a biomarker of response to sunitinib in metastatic clear cell renal cancer. Clin Cancer Res (2011) 17(18):6021-8. PMID: 21742806
Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol (2009) 27(6):884-90. PMID: 19114688
I am the lead for solid tumor research at Barts Cancer Institute. I also lead the genitourinary (GU) cancer group at BCI.
My work focuses on a spectrum of clinical studies from phase I to randomised phase III. The majority of the studies are translational phase II studies investigating novel targeted and immune therapies. They exploit functional imaging and tissue collection.
Alongside these trials, our research focuses on correlation of novel biomarkers and aims to define markers that are of prognostic value and can predict response or resistance to therapy.
I have written over 100 peer review papers in this area and have grant income from national and international funding bodies.
I am on the editorial board of a number of journals and am part of the faculty for the major global oncology meetings.
Molecular and histopathology directed therapy for advanced bladder cancer. Alifrangis C, McGovern U, Freeman A et al. Nat Rev Urol (2019) 16(2) 465-483
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma. Albiges L, Powles T, Staehler M et al. Eur Urol (2019) 76(2) 151-156
Erratum to 'Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma' [Eur J Cancer 108 (February 2019) 33-40]. Auvray M, Auclin E, Barthelemy P et al. Eur J Cancer (2019) (2)
Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer. Woolston A, Khan K, Spain G et al. Cancer Cell (2019) 36(2) 35-50.e9
Performance and cost of a renal cancer specialist multidisciplinary team meeting: Results from 1500 discussions Neves JB, Shepherd S, Cullen D et al. Journal of Clinical Urology (2019) 12(7) 314-319
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. Sternberg CN, Loriot Y, James N et al. Eur Urol (2019) 76(2) 73-81
The adjuvant treatment of kidney cancer: a multidisciplinary outlook. Porta C, Cosmai L, Leibovich BC et al. Nat Rev Nephrol (2019) 15(2) 423-433
Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma. Reply. Rini BI, Powles T N Engl J Med (2019) 380(2) 2582
Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. Grimm M-O, Bex A, De Santis M et al. Eur Urol (2019) (2)
Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME). De Bruijn RE, Mulders P, Jewett MA et al. Eur Urol (2019) (2)
I qualified from St Bartholomew’s Medical School in 1996 and trained in medical oncology at Imperial College. I completed post-graduate training in oncology in 2005 and received an MD from the University of London in 2006. My thesis was in mechanisms of resistance to therapy in urology cancers.